8-K: Scorpius Holdings Amends Convertible Note Terms, Secures New Short-Term Debt

Scorpius Holdings, Inc. has amended its senior secured convertible note, introducing a lower conversion price tied to market performance and removing shareholder approval requirements, while also securing a new $485,000 non-convertible promissory note.

Summary

• Amended a Senior Secured Convertible Note with 3i, LP, originally for $12,416,667, dated December 6, 2024, and previously amended on February 13, 2025, and May 1, 2025.
• The conversion price of the convertible note was changed to the lower of $0.06 per share or 55% of the average of the three lowest traded prices during the twenty trading days prior to conversion.
• Removed the requirement for stockholder approval to increase authorized common stock or effect a reverse stock split, which was previously needed for full conversion of the note.
• Removed the limitation that restricted the investor to convert only $2,700,000 of principal until stockholder approval was obtained.
• The company currently lacks sufficient authorized and unreserved shares to satisfy its obligation to reserve 100% of shares issuable upon full conversion of the note.
• If the convertible note were to fully convert at a conversion price of $0.033 (representing 55% of the Market Price as of the report date), it would result in the issuance of 345,243,790 shares for the principal amount, plus an additional 93,215,821 shares for interest and Make-Whole Amount.
• Issued a new non-convertible promissory note for $485,000 to 3i, LP, accruing interest at 5.0% per annum.
• The new promissory note matures on the earliest of August 31, 2025, a Corporate Event, or an Event of Default.
• A 5% premium on the principal amount is payable upon maturity, redemption, or prepayment of the new promissory note.
• The holder of the new promissory note has the right, at its sole discretion, to require redemption of the entire outstanding balance, together with all accrued interest and the 5% premium, using up to 100% of the gross proceeds from any subsequent financing.

Sentiment

Score: 2

Explanation: The filing indicates significant financial distress and a reliance on highly dilutive financing. The amended convertible note terms are very unfavorable for existing shareholders, and the new short-term debt suggests immediate liquidity challenges. The lack of sufficient authorized shares for conversion is a major red flag.

Positives

• Secured additional short-term financing of $485,000, addressing immediate liquidity needs.

Negatives

• The revised convertible note terms introduce a 'toxic' conversion feature (55% of market price), which can lead to significant dilution for existing shareholders, especially if the stock price declines.
• Removal of the stockholder approval requirement for increasing authorized shares or a reverse stock split eliminates a key safeguard for existing shareholders against excessive dilution.
• The company explicitly states it does not have enough authorized shares to fully satisfy its conversion obligations under the convertible note, indicating a potential future capital structure issue or default risk.
• The new $485,000 promissory note is a short-term loan with a high effective cost (5% interest + 5% premium in less than 2 months), suggesting urgent liquidity needs.
• The new promissory note includes a clause allowing the holder to demand repayment from future financing proceeds, potentially hindering future capital raises for operational needs.
• The company is incurring additional debt from the same institutional investor, potentially increasing its reliance on this single investor.

Risks

• Significant Share Dilution: The amended conversion price, tied to 55% of the market price, and the removal of conversion limitations could lead to substantial dilution of existing shareholders' equity.
• Insufficient Authorized Shares: The company does not have enough authorized shares to fully convert the existing convertible note, which could lead to a default or necessitate further dilutive actions like a reverse stock split or a large increase in authorized shares.
• Short-Term Liquidity Pressure: The issuance of a short-term promissory note maturing by August 31, 2025, indicates immediate and pressing liquidity needs.
• High Cost of Debt: The 5% interest rate plus a 5% premium on the $485,000 promissory note represents a high effective cost for short-term financing.
• Future Financing Constraints: The clause in the new promissory note allowing the holder to demand repayment from future financing proceeds could make it difficult for the company to raise capital for other strategic purposes.
• Default Risk: Events of default for the new promissory note include failure to pay indebtedness over $150,000 to any third party or an event of default under any other outstanding promissory notes.
• Control by Investor: Increased reliance on a single institutional investor (3i, LP) through both convertible and non-convertible debt instruments.

Future Outlook

The filing indicates a near-term need for capital, evidenced by the short maturity of the new promissory note. The amendments to the convertible note suggest a strategy to facilitate conversion by the holder, potentially leading to significant future dilution, especially given the company's current lack of sufficient authorized shares to cover full conversion.

Management Comments

• Jeffrey Wolf, Chief Executive Officer of Scorpius Holdings, Inc., signed the agreement on behalf of the company.
• Maier J. Tarlow, Manager on Behalf Of 3i Management LLC, The GP of 3i LP, signed on behalf of the Holder.

Industry Context

This filing reflects a common pattern for small-cap companies, particularly those in early stages or facing financial challenges, to secure financing through convertible debt with potentially dilutive terms. The use of a 'toxic' conversion feature (variable conversion price) and short-term, high-cost debt from the same investor is often seen when traditional financing avenues are limited, indicating a potentially distressed financial situation or significant capital needs for operations.

Comparison to Industry Standards

• The terms of the amended convertible note, specifically the conversion price set at 55% of the market price, are indicative of highly dilutive financing instruments often referred to as 'death spiral' or 'toxic' convertibles. These terms are significantly more aggressive than standard convertible notes issued by financially stable companies, which typically feature fixed conversion premiums above the current share price. For example, a healthy company might issue a convertible note with a conversion premium of 20-30% above the stock price at issuance, whereas Scorpius's terms allow conversion at a discount to market.
• The short maturity (August 31, 2025) and 5% premium on the new $485,000 promissory note also suggest a higher cost of capital compared to typical corporate loans or lines of credit for established businesses, which would generally have lower interest rates and longer repayment periods. This type of financing is more akin to bridge loans or distressed debt, often seen in companies like Sorrento Therapeutics (OTC: SRNEQ) during its bankruptcy proceedings or other micro-cap biotech firms struggling with cash burn and limited access to conventional capital markets.

Related Party Transactions

• The new $485,000 non-convertible promissory note was issued to 3i, LP, the same institutional investor that holds the Senior Secured Convertible Note.

Stakeholder Impact

• Shareholders: Highly negative impact due to significant potential dilution from the amended convertible note terms and the removal of shareholder protections. The current lack of authorized shares for conversion also creates uncertainty.
• Creditors: The new promissory note provides a short-term repayment obligation with a premium, and the holder of this note has a strong position to demand repayment from future financings.

Next Steps

• The company will need to address the insufficient number of authorized shares to satisfy its convertible note obligations, potentially through a reverse stock split or an increase in authorized shares.
• The company will need to repay the $485,000 promissory note by August 31, 2025, or secure new financing to do so.
• The holder of the new promissory note may exercise its right to demand repayment from any future financing.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, resorting to highly dilutive and unfavorable financing terms. The amended convertible note introduces a 'toxic' conversion feature that will likely lead to massive dilution for existing shareholders as the investor converts at a discount to market price. The removal of shareholder approval for increasing authorized shares or a reverse split further exacerbates this risk. The immediate need for a short-term, high-cost promissory note, coupled with the explicit statement that the company lacks sufficient authorized shares for full conversion, signals critical liquidity issues and a precarious capital structure. These factors collectively point to a significant erosion of shareholder value and high risk of further downside.

Keywords

Scorpius Holdings, SEC Filing, 8-K, Convertible Note, Promissory Note, Debt Financing, Share Dilution, Corporate Governance, Capital Raise, Financial Restructuring, Toxic Debt, 3i LP